The type 2 diabetes treatment armamentarium has a place for Novo Nordisk AS's proposed combination product, but FDA should try to more definitively to determine which patients would ideally benefit, advisory committee members concluded.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?